1 Table of Contents

1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5

2 Introduction 6
2.1 Total Artificial Heart Overview 6

3 Products under Development 7
3.1 Total Artificial Heart - Pipeline Products by Stage of Development 7
3.2 Total Artificial Heart - Pipeline Products by Territory 8
3.3 Total Artificial Heart - Pipeline Products by Regulatory Path 9
3.4 Total Artificial Heart - Pipeline Products by Estimated Approval Date 10
3.5 Total Artificial Heart - Ongoing Clinical Trials 11

4 Total Artificial Heart - Pipeline Products under Development by Companies 12
4.1 Total Artificial Heart Companies - Pipeline Products by Stage of Development 12
4.2 Total Artificial Heart - Pipeline Products by Stage of Development 13

5 Total Artificial Heart Companies and Product Overview 14
5.1 Abiomed Inc Company Overview 14
5.1.1 Abiomed Inc Pipeline Products & Ongoing Clinical Trials Overview 14
5.2 BiVacor Pty Ltd Company Overview 15
5.2.1 BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 15
5.3 Carmat SAS Company Overview 16
5.3.1 Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview 16
5.4 Cleveland Heart Inc Company Overview 19
5.4.1 Cleveland Heart Inc Pipeline Products & Ongoing Clinical Trials Overview 19
5.5 Foster-Miller Inc (Ictive) Company Overview 20
5.5.1 Foster-Miller Inc (Ictive) Pipeline Products & Ongoing Clinical Trials Overview 20
5.6 Indian Institute of Technology Kharagpur Company Overview 21
5.6.1 Indian Institute of Technology Kharagpur Pipeline Products & Ongoing Clinical Trials Overview 21
5.7 OregonHeart Inc (Ictive) Company Overview 22
5.7.1 OregonHeart Inc (Ictive) Pipeline Products & Ongoing Clinical Trials Overview 22
5.8 ReliantHeart, Inc. Company Overview 23
5.8.1 ReliantHeart, Inc. Pipeline Products & Ongoing Clinical Trials Overview 23
5.9 Scandivian Real Heart AB Company Overview 24
5.9.1 Scandivian Real Heart AB Pipeline Products & Ongoing Clinical Trials Overview 24
5.10 Syncardia Systems LLC Company Overview 25
5.10.1 Syncardia Systems LLC Pipeline Products & Ongoing Clinical Trials Overview 25
5.11 TEDA Intertiol Cardiovascular Hospital Company Overview 32
5.11.1 TEDA Intertiol Cardiovascular Hospital Pipeline Products & Ongoing Clinical Trials Overview 32
5.12 University of Tokyo Company Overview 33
5.12.1 University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview 33

6 Total Artificial Heart- Recent Developments 34
6.1 May 17, 2018: Artificial heart technology gets federal funding 34
6.2 May 15, 2018: Micron Solutions Reports 2018 First Quarter Results 34
6.3 May 14, 2018: Real Heart: Continued progress in the second preclinical trial 35
6.4 May 03, 2018: Abiomed Announces Q4 FY 2018 Revenue of $174 Million, Up 40%, and Total Year Revenue of $594 Million, Up 33%, Over Prior Year 36
6.5 Apr 05, 2018: CARMAT: Continuing Progress in Line with the Objective of Obtaining CE Marking in 2019 37
6.6 Mar 30, 2018: Abiomed to Appoint New Chief Fincial Officer Todd A. Trapp 38
6.7 Mar 26, 2018: Micron Solutions Reports 2017 Fourth Quarter and Year End Results 39
6.8 Feb 27, 2018: Scandivian Real Heart Selects AdaCore Embedded Software Development Platform for Revolutiory Artificial Heart 40
6.9 Feb 20, 2018: CARMAT Advances the Intertiolization of the PIVOTAL Study and Obtains the Approval to Perform Implants in Denmark 41
6.10 Feb 13, 2018: Carmat: 2017 Annual Results 42
6.11 Feb 01, 2018: Abiomed Announces Q3 FY 2018 Record Revenue of $154 Million, Up 34% Over Prior Year 43
6.12 Jan 08, 2018: Abiomed Announces Prelimiry Q3 FY 2018 Revenue of $154M, Up 34% Over Prior Year 44
6.13 Dec 08, 2017: Micron Solutions Desigtes Mr. E. P. Marinos as a Director Emeritus and Appoints Mr. Andrei Soran to its Board of Directors 45
6.14 Nov 27, 2017: First Implantation in the Czech Republic within the Framework of the PIVOTAL Study Intertiol Expansion 46
6.15 Nov 13, 2017: Micron Solutions Reports 2017 Third Quarter Results 46
6.16 Oct 30, 2017: CARMAT accelerates the intertiolization of the PIVOTAL study and obtains the approval to perform implants in the Czech Republic 48
6.17 Oct 26, 2017: Abiomed Announces Q2 FY 2018 Revenue of $132.8 Million, Up 29% and Record U.S. Patient Utilization, Up 33% 49
6.18 Oct 23, 2017: Intertiol implant of the CARMAT heart 49
6.19 Oct 19, 2017: Abiomed’s Impella Technology that Ebles Heart Recovery Showcased at TCT 2017 With More Than 30 Presentations 50
6.20 Oct 05, 2017: CARMAT expands its PIVOTAL study intertiolly, in line with its clinical strategy and CE marking process 51
6.21 Sep 29, 2017: Scandivian Real Heart Announces the Progress in Total Artificial Heart 52
6.22 Sep 29, 2017: Scandivian Real Heart: Progress in Real Heart’s Product Development 52
6.23 Sep 26, 2017: CARMAT: 2017 Half-Year Results 52
6.24 Sep 01, 2017: CARMAT appoints Francesco Arecchi, previously Product Mager EMEA Structural Heart at Abbott, as Marketing Mager 54
6.25 Aug 28, 2017: Abiomed Announces Resigtion of Chief Fincial Officer and Welcomes Back Former Chief Fincial Officer as Consultant 55
6.26 Aug 11, 2017: Micron Solutions Reports 2017 Second Quarter Results 55
6.27 Jul 27, 2017: Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year 57
6.28 Jul 24, 2017: Micron Solutions Appoints Rodd E. Friedman to its Board of Directors 58
6.29 Jul 06, 2017: CARMAT Appoints Wenzel Hurtak, Previously Business Director New Products at Contract Medical Intertiol GmbH, as Director of Manufacturing 58
6.30 Jul 03, 2017: Real Heart plans to perform next series of tests in the United States 59
6.31 Jul 03, 2017: Real Heart plans to perform next series of tests in the United States 59
6.32 Jun 21, 2017: Italian Boy Becomes Youngest Patient Bridged to Transplant with the SynCardia temporary Total Artificial Heart 60

7 Appendix 61
7.1 Methodology 61
7.2 About GlobalData 64
7.3 Contact Us 64
7.4 Disclaimer 64